RxDoctor Payments DataLook up a doctor →

Jan Pattanayak, MD

Interventional Cardiology · Asheville, NCNPI 1699860338

Payments from drug & device makers

$255,235in general payments, 2019–2025

Across 561 payments — averaging $454.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$117K
  • Lilly USA, LLC$62K
  • AstraZeneca$18K
  • Abbott$16K
  • Pfizer$14K
  • Biotronik Inc.$12K
  • plus $15K from 21 others

What the payments were for

  • Consulting fees$5,1002%
  • Speaking & faculty fees$184,50387%
  • Travel & lodging$10,9765%
  • Food & beverage$11,6425%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$255,235 in reported general payments places this provider in the 80th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$171,834
Medicare patients
571
Services billed
1,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban466$511,777
JardianceEmpagliflozin188$187,559
FarxigaDapagliflozin Propanediol84$109,520
EntrestoSacubitril/Valsartan69$88,051
XareltoRivaroxaban99$83,714
Repatha SureclickEvolocumab31$43,892
WegovySemaglutide11$14,943
Repatha SyringeEvolocumab16$12,283
Praluent PenAlirocumab13$11,459
BrilintaTicagrelor14$8,388
Metoprolol Succinate416$4,956
Atorvastatin Calcium508$4,617
ClopidogrelClopidogrel Bisulfate391$4,584
Dofetilide13$3,923
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14,193$511,777466 claims
Boehringer IngelheimJardiance$117,399$187,559188 claims
AstraZenecaFarxiga, Brilinta$18,383$117,90898 claims
NovartisEntresto$16$88,05169 claims
Johnson & JohnsonXarelto$7,763$83,71499 claims
Novo NordiskWegovy$185$14,94311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →